Author(s): Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL
Abstract Share this page
Abstract Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
This article was published in Nat Rev Cancer
and referenced in Journal of Cytology & Histology